Transfer of P14 CD8+ Teff pre-cultured with CD73 inhibitor-pretreated activated CD28KOCD8+ T cells (86.2% survival, group III) resulted in significantly increased survival of tumor-bearing mice compared to mice receiving P14 CD8+ Teff cells pre-cultured with activated CD28KOCD8+ T cells (group II) (p < 0.01). This evidence concerns the gene CD8A and neoplasm.